ENTA

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Sell rating on Enanta Pharmaceuticals (ENTA – Research Report), with a price target of $35.00. The company's shares closed last Thursday at $44.01, close to its 52-week low of $40.37. According to TipRanks.com, Bayko is a 4-star analyst with an average return of 5.1% and a 40.8% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Enanta Pharmaceuticals with a $67.89 average price target.
https://www.tipranks.com/news/blurbs/evercore-isi-maintains-a-sell-rating-on-enanta-pharmaceuticals-enta-2?utm_source=advfn.com&utm_medium=referral